Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2611)	2/18/2000 1:18:00 PM
From: Chris W.	Read Replies (1) \| Respond to of 2742

Does this have any bearing on CIST technology? Alexion is one of the flavors of the month. Tuesday February 15, 6:30 am Eastern Time Company Press Release SOURCE: Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals and The Brigham and Women's Hospital Form Collaboration to Develop Novel Anti-Inflammatory Antibody - Novel Monoclonal Antibody Shows Promise in Vascular Damage Models - NEW HAVEN, Conn., Feb. 15 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - news) today announced that it has entered into both a collaborative research and a license agreement with The Brigham and Women's Hospital, Inc. covering a newly discovered pathway of complement mediated inflammation. Under the license agreement, Alexion received exclusive worldwide rights to these novel anti-inflammatory technologies and to associated therapeutic products, including an already identified monoclonal antibody. These products are expected to have broad therapeutic application in patients suffering from atherosclerosis, unstable angina, strokes and other vascular disorders.